Eyenovia Inc (EYEN)

May 19, 2025, 5:30 PM EDT - 18 days ago

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

Apr 10, 2025, 7:00 AM EDT - 2 months ago

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

Mar 20, 2025, 7:00 AM EDT - 2 months ago

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

Feb 26, 2025, 7:00 AM EST - 3 months ago

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

Feb 24, 2025, 7:00 AM EST - 3 months ago

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

Feb 5, 2025, 7:00 AM EST - 4 months ago

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

Jan 28, 2025, 4:05 PM EST - 4 months ago

Eyenovia Announces 1-for-80 Reverse Stock Split

Jan 15, 2025, 7:00 AM EST - 5 months ago

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

Jan 6, 2025, 7:00 AM EST - 5 months ago

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

Dec 6, 2024, 8:00 AM EST - 6 months ago

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

Nov 22, 2024, 7:00 AM EST - 7 months ago

Eyenovia Provides Update on Restructuring Efforts

Nov 15, 2024, 1:15 PM EST - 7 months ago

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

Nov 15, 2024, 7:07 AM EST - 7 months ago

Eyenovia to discontinue late-stage study for eye drug

Nov 15, 2024, 7:00 AM EST - 7 months ago

Eyenovia Provides Update on Phase 3 CHAPERONE Study

Nov 12, 2024, 10:42 PM EST - 7 months ago

Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 7 months ago

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

Oct 16, 2024, 7:00 AM EDT - 8 months ago

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Oct 1, 2024, 7:00 AM EDT - 8 months ago

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

Sep 27, 2024, 8:30 AM EDT - 9 months ago

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

Sep 26, 2024, 7:00 AM EDT - 9 months ago

Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

Sep 9, 2024, 3:00 AM EDT - 9 months ago

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

Sep 5, 2024, 7:00 AM EDT - 9 months ago

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

Sep 3, 2024, 7:00 AM EDT - 9 months ago

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

Aug 23, 2024, 11:42 AM EDT - 10 months ago

Eyenovia Announces Closing of Public Offering

Aug 22, 2024, 2:20 PM EDT - 10 months ago

Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?

Aug 21, 2024, 9:29 AM EDT - 10 months ago

Eyenovia Announces Pricing of $5.14 Million Public Offering

Aug 20, 2024, 5:09 PM EDT - 10 months ago

Eyenovia, Inc. Announces Proposed Public Offering

Aug 12, 2024, 11:07 PM EDT - 10 months ago

Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:05 PM EDT - 10 months ago

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 7:00 AM EDT - 10 months ago

Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th

Aug 7, 2024, 5:11 PM EDT - 10 months ago

Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.

Aug 7, 2024, 8:00 AM EDT - 10 months ago

Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States

Jul 30, 2024, 8:00 AM EDT - 11 months ago

Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease

Jul 23, 2024, 7:00 AM EDT - 11 months ago

Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease

Jul 1, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

NBY

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Eyenovia Announces Pricing of $5M Registered Direct Offering

May 17, 2024, 9:12 PM EDT - 1 year ago

Eyenovia, Inc. (EYEN) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:01 PM EDT - 1 year ago

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

May 14, 2024, 7:00 AM EDT - 1 year ago

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Mar 18, 2024, 8:52 PM EDT - 1 year ago

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 13, 2024, 7:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

Mar 5, 2024, 8:00 AM EST - 1 year ago

Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery

Mar 4, 2024, 6:08 PM EST - 1 year ago

US FDA approves Eyenovia's eye drug, Formosa Pharma says

Feb 26, 2024, 2:45 PM EST - 1 year ago

Eyenovia: Racing Toward The Finish Line

Feb 13, 2024, 7:00 AM EST - 1 year ago

Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility